PB1997: DARATUMUMAB, LENALIDOMIDE, BORTEZOMIB, AND DEXAMETHASONE FOR TRANSPLANT-ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: OUTCOME AND SAFETY PROFILE FROM A REAL-WORLD SINGLE CENTER EXPERIENCE

• H. Elsabah,
• N. Kassem,
• A. Gulied,
• R. Taha,
• H. Elomri,
• H. Cherif

Affiliations

H. Elsabah

1 Hematology

N. Kassem

2 Pharmacy department, Hamad medical corporation, Doha, Qatar

A. Gulied

2 Pharmacy department, Hamad medical corporation, Doha, Qatar

R. Taha

1 Hematology

H. Elomri

1 Hematology

H. Cherif

1 Hematology